Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial

BACKGROUND: Tocilizumab, an interleukin 6 receptor (IL-6R) antagonist monoclonal antibody, has shown efficacy in patients with coronavirus disease 2019 (COVID-19) pneumonia, but the optimal dose is unknown. METHODS: Patients hospitalized for moderate to severe COVID-19 pneumonia were randomized 1:1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Princy N, Hernández-Sánchez, Jules, Nagel, Sandra, Feng, Yuning, Cai, Fang, Rabin, Joseph, Morse, Caryn G, Nadig, Nandita R, Ashraf, Obaid, Gotur, Deepa B, McComsey, Grace A, Gafoor, Khalid, Perin, Patrick, Thornton, Sarah C, Stubbings, William, Lin, Celia J F, Tsai, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690270/
https://www.ncbi.nlm.nih.gov/pubmed/35024375
http://dx.doi.org/10.1093/ofid/ofab608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690270/
https://www.ncbi.nlm.nih.gov/pubmed/35024375
http://dx.doi.org/10.1093/ofid/ofab608

Ejemplares similares